PGP9.5 As a candidate tumor marker for non-small-cell lung cancer

Kenji Hibi, William H. Westra, Michael Borges, Steve Goodman, David Sidransky, Jin Jen

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

PGP9.5 is a neurospecific peptide that functions to remove ubiquitin from ubiquitinated proteins and prevents them from targeted degradation by proteasomes. Using the serial analysis of gene expression method (SAGE), we observed that the PGP9.5 transcript was highly expressed in primary lung cancers and lung cancer cell lines but was not detectable in the normal lung. Here we examined the expression of PGP9.5 protein in normal lung epithelium, lung tumor cell lines, and 98 resected primary non-small-cell lung carcinomas (NSCLCs). We found PGP9.5 reactivity in normal lung in a pattern compatible with K-cells of the diffuse neuroendocrine system. However, the PGP9.5 was present in both small-cell lung cancer (SCLC) and NSCLC cell lines (22/24) independent of neuronal differentiation. In primary NSCLCs, 54% (53/98) of the cases had positive PGP9.5 staining, and the expression of protein was strongly associated with pathological stage of the cancer. It was present in 44% (29/66) of stage I NSCLCs and in 75% (24/32) of stage II and IIIA NSCLCs (p = 0.0032). These results suggest that the increased expression of PGP9.5 is specifically associated with lung cancer development and may serve as a potential marker for the detection of lung cancer.

Original languageEnglish (US)
Pages (from-to)711-715
Number of pages5
JournalAmerican Journal of Pathology
Volume155
Issue number3
StatePublished - Sep 1999
Externally publishedYes

Fingerprint

Tumor Biomarkers
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Lung
Ubiquitinated Proteins
Cell Line
Neurosecretory Systems
Small Cell Lung Carcinoma
Proteasome Endopeptidase Complex
Ubiquitin
Tumor Cell Line
Proteins
Epithelium
Staining and Labeling
Gene Expression
Peptides
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Hibi, K., Westra, W. H., Borges, M., Goodman, S., Sidransky, D., & Jen, J. (1999). PGP9.5 As a candidate tumor marker for non-small-cell lung cancer. American Journal of Pathology, 155(3), 711-715.

PGP9.5 As a candidate tumor marker for non-small-cell lung cancer. / Hibi, Kenji; Westra, William H.; Borges, Michael; Goodman, Steve; Sidransky, David; Jen, Jin.

In: American Journal of Pathology, Vol. 155, No. 3, 09.1999, p. 711-715.

Research output: Contribution to journalArticle

Hibi, K, Westra, WH, Borges, M, Goodman, S, Sidransky, D & Jen, J 1999, 'PGP9.5 As a candidate tumor marker for non-small-cell lung cancer', American Journal of Pathology, vol. 155, no. 3, pp. 711-715.
Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 As a candidate tumor marker for non-small-cell lung cancer. American Journal of Pathology. 1999 Sep;155(3):711-715.
Hibi, Kenji ; Westra, William H. ; Borges, Michael ; Goodman, Steve ; Sidransky, David ; Jen, Jin. / PGP9.5 As a candidate tumor marker for non-small-cell lung cancer. In: American Journal of Pathology. 1999 ; Vol. 155, No. 3. pp. 711-715.
@article{963d49be14374ab795101bd0f615b20d,
title = "PGP9.5 As a candidate tumor marker for non-small-cell lung cancer",
abstract = "PGP9.5 is a neurospecific peptide that functions to remove ubiquitin from ubiquitinated proteins and prevents them from targeted degradation by proteasomes. Using the serial analysis of gene expression method (SAGE), we observed that the PGP9.5 transcript was highly expressed in primary lung cancers and lung cancer cell lines but was not detectable in the normal lung. Here we examined the expression of PGP9.5 protein in normal lung epithelium, lung tumor cell lines, and 98 resected primary non-small-cell lung carcinomas (NSCLCs). We found PGP9.5 reactivity in normal lung in a pattern compatible with K-cells of the diffuse neuroendocrine system. However, the PGP9.5 was present in both small-cell lung cancer (SCLC) and NSCLC cell lines (22/24) independent of neuronal differentiation. In primary NSCLCs, 54{\%} (53/98) of the cases had positive PGP9.5 staining, and the expression of protein was strongly associated with pathological stage of the cancer. It was present in 44{\%} (29/66) of stage I NSCLCs and in 75{\%} (24/32) of stage II and IIIA NSCLCs (p = 0.0032). These results suggest that the increased expression of PGP9.5 is specifically associated with lung cancer development and may serve as a potential marker for the detection of lung cancer.",
author = "Kenji Hibi and Westra, {William H.} and Michael Borges and Steve Goodman and David Sidransky and Jin Jen",
year = "1999",
month = "9",
language = "English (US)",
volume = "155",
pages = "711--715",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - PGP9.5 As a candidate tumor marker for non-small-cell lung cancer

AU - Hibi, Kenji

AU - Westra, William H.

AU - Borges, Michael

AU - Goodman, Steve

AU - Sidransky, David

AU - Jen, Jin

PY - 1999/9

Y1 - 1999/9

N2 - PGP9.5 is a neurospecific peptide that functions to remove ubiquitin from ubiquitinated proteins and prevents them from targeted degradation by proteasomes. Using the serial analysis of gene expression method (SAGE), we observed that the PGP9.5 transcript was highly expressed in primary lung cancers and lung cancer cell lines but was not detectable in the normal lung. Here we examined the expression of PGP9.5 protein in normal lung epithelium, lung tumor cell lines, and 98 resected primary non-small-cell lung carcinomas (NSCLCs). We found PGP9.5 reactivity in normal lung in a pattern compatible with K-cells of the diffuse neuroendocrine system. However, the PGP9.5 was present in both small-cell lung cancer (SCLC) and NSCLC cell lines (22/24) independent of neuronal differentiation. In primary NSCLCs, 54% (53/98) of the cases had positive PGP9.5 staining, and the expression of protein was strongly associated with pathological stage of the cancer. It was present in 44% (29/66) of stage I NSCLCs and in 75% (24/32) of stage II and IIIA NSCLCs (p = 0.0032). These results suggest that the increased expression of PGP9.5 is specifically associated with lung cancer development and may serve as a potential marker for the detection of lung cancer.

AB - PGP9.5 is a neurospecific peptide that functions to remove ubiquitin from ubiquitinated proteins and prevents them from targeted degradation by proteasomes. Using the serial analysis of gene expression method (SAGE), we observed that the PGP9.5 transcript was highly expressed in primary lung cancers and lung cancer cell lines but was not detectable in the normal lung. Here we examined the expression of PGP9.5 protein in normal lung epithelium, lung tumor cell lines, and 98 resected primary non-small-cell lung carcinomas (NSCLCs). We found PGP9.5 reactivity in normal lung in a pattern compatible with K-cells of the diffuse neuroendocrine system. However, the PGP9.5 was present in both small-cell lung cancer (SCLC) and NSCLC cell lines (22/24) independent of neuronal differentiation. In primary NSCLCs, 54% (53/98) of the cases had positive PGP9.5 staining, and the expression of protein was strongly associated with pathological stage of the cancer. It was present in 44% (29/66) of stage I NSCLCs and in 75% (24/32) of stage II and IIIA NSCLCs (p = 0.0032). These results suggest that the increased expression of PGP9.5 is specifically associated with lung cancer development and may serve as a potential marker for the detection of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032888057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032888057&partnerID=8YFLogxK

M3 - Article

C2 - 10487828

AN - SCOPUS:0032888057

VL - 155

SP - 711

EP - 715

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -